Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

NCT07457528 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Resectable Esophageal Squamous Cell Carcinoma

Interventions

DRUG: HLX10
DRUG: Chemotherapy
DRUG: Nimotuzumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital